Syneron Medical Appoints Jonathan Pearson as Executive Vice
President of Business Development, Topical Products
YOKNEAM, Israel, Nov. 7, 2012 /PRNewswire/ -- Syneron Medical
Ltd. (NASDAQ: ELOS), www.syneron.com, the leading global aesthetic
device company, announced today that Jonathan Pearson has been appointed Executive
Vice President of Business Development, Topical Products, effective
November 19, 2012. In this position,
Mr. Pearson will have global responsibility for Syneron's business
of topical cosmetic products, which currently includes the elure™
Advanced Skin Brightening product family. He will report to
Louis P. Scafuri, Chief Executive
Officer of Syneron.
(Logo: http://photos.prnewswire.com/prnh/20120528/535447)
Prior to joining Syneron, from 2003 to 2012, Mr. Pearson was a
corporate officer at TRIA Beauty, Inc., a developer and marketer of
light-based skincare products for use in the home. Mr. Pearson was
a co-founder of the company and served as Asia Pacific Region
Manager, with direct responsibility for establishing and managing
the company's Asian operations. Prior to co-founding TRIA Beauty,
Mr. Pearson was employed from 2001 to 2003 at Lumenis, Ltd., a
developer, manufacturer and distributor of a broad range of medical
lasers and energy delivery equipment for surgical, aesthetic and
ophthalmic applications. At Lumenis, Mr. Pearson was Executive Vice
President, Asia-Pacific Operations, and served as a corporate
officer. Mr. Pearson joined Lumenis when it merged with Coherent
Inc., where he served from 1994 to 2001, ultimately as Director,
Asia-Pacific, managing the
company's direct operations in Japan and the
People's Republic of China.
Mr. Pearson holds a bachelor's degree in Political Science from
the University of Washington and a
master's degree in International Management from Thunderbird School
of Global Management. He is bi-lingual in the English and Japanese
languages, and has extensive experience living in Asia.
Mr. Scafuri, said, "Jon Pearson
has a proven track record of success in the aesthetic industry,
with unique and relevant global experience in both the professional
and consumer markets. We believe he is ideally suited to help us
capitalize on the tremendous opportunity for our elure™ Advanced
Skin Brightening product family, as well as further expand the
topical segment of our business. His deep familiarity with and
understanding of Asian markets will be particularly valuable, given
that this geography represents the largest opportunity for elure™.
We look forward to welcoming Jon to the team and collaborating with
him to grow our topical business."
About Syneron Medical Ltd.
Syneron Medical Ltd. – a
company devoted to real technology, real science and real results –
is the leading global aesthetic device company with a comprehensive
product portfolio and a global distribution footprint. The
Company's technology enables physicians to provide advanced
solutions for a broad range of medical-aesthetic applications
including body contouring, hair removal, wrinkle reduction,
rejuvenation of the skin's appearance through the treatment of
superficial benign vascular and pigmented lesions, and the
treatment of acne, leg veins and cellulite. The Company sells
its products under two distinct brands, Syneron and Candela.
The Company's aspiration and commitment to innovation expands
Syneron's offering beyond medical device into the largest in-demand
applications in beauty - skin lightening. Founded in 2000,
the corporate, R&D, and manufacturing headquarters for Syneron
Medical Ltd. are located in Israel. Syneron also has R&D and
manufacturing operations in the US. The company markets and
services and supports its products in 86 countries. It has offices
in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide. Additional information can be found at
www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any
statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the company
will not meet stated goals, as well as the risks set forth in
Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and
the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
SOURCE Syneron Medical Ltd.